Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail to Achieve a Complete Response to Initial Gleevec Treatment

NCT00250042 is registered in ClinicalTrials.gov with New Mexico Cancer Research Alliance as lead sponsor.

NCT NCT00250042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00250042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail to Achieve a Complete Response to Initial Gleevec Treatment
Lead sponsor
New Mexico Cancer Research Alliance
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2004
Completion date
March 31, 2006
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, leukemia, other